News
News
Bad Berka, Germany
With over 350 participants from 30 countries representing the 5 continents, the 1st World Congress on GA68 and PRRNT marks a historical moment in the history of imaging and therapy for individuals with Neuroendocrine tumors as well as other diseases that can be imaged with GA68.
Please enjoy the photo gallery below. Viewing on an iPhone, iPad or other device that does not support flash? click here.
The final program has been announced for the 1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy to be held June 23rd-26th, 2011 in Bad Berka, Germany.
Please click here to download the agenda.
1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy
THERANOSTICS – on the Way to Personalized Medicine
Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin anlogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to a young man of 20 who was walking and playing soccer, Prof. Dr. med. Richard P. Baum has been passionate about Peptide
Read more: 1st World Congress on Ga-68 and Peptide Receptor...
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers.
Published in Journal of Clinical Oncology, 2011 May 9;[Epub Ahead of Print], A Imhof, P Brunner, N Marincek, M Briel, C Schindler, H Rasch, HR Mäcke, C Rochlitz, J Müller-Brand, MA Walter
To read a review of the JCO article please visit OncologyStat (free registration is required to read the summary of findings.)
January 2011 - European Neuroendocrine Tumor Society has certified Zentralklink Bad Berka as an ENETS Centers of Excellence. The certification states that center meets all quality standards defined by ENETS for interdisciplinary diagnostics, medical treatment and aftercare of patients with neuroendocrine tumors. Click here to download a copy of the certificate.